Scarica l'app Stockscreener
2.97
0.00%
0.00
Dopo l'orario di chiusura:
2.97
Precedente Chiudi:
$2.97
Aprire:
$2.945
Volume 24 ore:
6,026
Relative Volume:
0.27
Capitalizzazione di mercato:
$26.11M
Reddito:
-
Utile/perdita netta:
$-30.16M
Rapporto P/E:
-8.7353
EPS:
-0.34
Flusso di cassa netto:
$-39.49M
1 W Prestazione:
+0.68%
1M Prestazione:
+2.59%
6M Prestazione:
-19.95%
1 anno Prestazione:
+905.76%
Intervallo 1D:
$2.945
$3.05
Intervallo di 1 settimana:
$2.89
$3.05
Portata 52W:
$0.28
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Confronta DARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.97 | 26.11M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Dare Bioscience granted extension by Nasdaq to regain compliance - Investing.com Australia
Daré Bioscience to Present at the Jones Healthcare and - GlobeNewswire
Daré's Game-Changing Strategy: Sildenafil Cream Heads to Prescription Market Earlier Than Expected - Stock Titan
Daré Bioscience Q1 EPS Estimate Increased by HC Wainwright - Defense World
Q1 EPS Estimate for Daré Bioscience Decreased by Analyst - Defense World
HC Wainwright Forecasts Daré Bioscience FY2029 Earnings - Defense World
Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Rises By 22.2% - Defense World
Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright - Defense World
Daré Bioscience Earnings Call: Strategic Progress Amid Challenges - TipRanks
Daré Bioscience (DARE) Anticipates Revenue Boost from Sildenafil Cream in 2025 - GuruFocus
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Home
Earnings call transcript: Dare Bioscience Q4 2024 focuses on women’s health innovations - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Daré Bioscience Reports Full Year 2024 Financial Results - MarketScreener
DARE BIOSCIENCE Earnings Results: $DARE Reports Quarterly Earnings - Nasdaq
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - TradingView
Daré Bioscience Reveals New Revenue Strategy: Sildenafil Cream Launch Coming Q4 2025 - Stock Titan
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Upcoming: Daré Bioscience Full Year Results Reveal Women's Health Innovation Progress - StockTitan
Daré Bioscience to Host Full Year 2024 Financial Results - GlobeNewswire
Daré Bioscience (DARE) Projected to Post Quarterly Earnings on Thursday - Defense World
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Should You Sell? - Defense World
Dare Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
Daré Bioscience and Theramex Announce Co-Development and - GlobeNewswire
Dare Bioscience and Theramex Announce Co-Development and Licensing Agreement for A Potential Biodegradable Long-Acting Contraceptive Implant - Marketscreener.com
Daré, Theramex partner on biodegradable contraceptive implant - Investing.com
Daré, Theramex partner on biodegradable contraceptive implant By Investing.com - Investing.com South Africa
Revolutionary Contraceptive Tech: This New Implant Actually Dissolves After Use - StockTitan
Dare Bioscience risks Nasdaq delisting over market value - MSN
Dare Bioscience (NASDAQ: DARE) Files 8-K with SEC Regarding Corporate Presentation - Defense World
Daré Bioscience to Present at BIO CEO Conference - TipRanks
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Dare Bioscience secures additional NIAID funding for HPV treatment By Investing.com - Investing.com Nigeria
Daré Bioscience Announces Funding Award Notice from the - GlobeNewswire
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development - The Manila Times
Revolutionary HPV Treatment Gets $12M Funding Boost: A New Hope for Cervical Health - StockTitan
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World
Daré Bioscience (NASDAQ:DARE) Prepares to Share Corporate Presentation on January 13, 2025 - Defense World
Geode Capital Management LLC Decreases Stock Holdings in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Above Fifty Day Moving Average – Time to Sell? - Defense World
Daré Bioscience Announces New Corporate Presentation - TipRanks
Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):